Fecal Microbiota Transplant and PD-1 blockade in Melanoma
黑色素瘤中的粪便微生物群移植和 PD-1 阻断
基本信息
- 批准号:10441408
- 负责人:
- 金额:$ 50.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-06-01 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:16S ribosomal RNA sequencingAgeAntitumor ResponseB-LymphocytesBacteriaBacteroidesBifidobacteriumBindingBioinformaticsBiometryCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCD8B1 geneCTLA4 blockadeCXCR6 geneCell MaturationCell physiologyCellsCessation of lifeClinicalClinical TrialsCorrelative StudyCytotoxic T-LymphocytesDendritic CellsDietEtiologyEvaluationExhibitsExperimental NeoplasmsFailureFecesFrequenciesFunding AgencyGerm-FreeHumanImmuneImmune responseImmunologicsImmunosuppressionIn VitroInnate Immune ResponseIntestinesInvestigationLigandsLiverMetagenomicsMetastatic Neoplasm to the LiverModelingMonoclonal AntibodiesMusNon-Small-Cell Lung CarcinomaOutcomePD-1 blockadePD-1/PD-L1PatientsPharmaceutical PreparationsPlayPublishingRNARegulatory T-LymphocyteRenal carcinomaReportingResearch PersonnelResistanceRoleSystems BiologyT cell responseT-LymphocyteT-cell inflamedTestingTimeTumor AntigensTumor-Infiltrating LymphocytesUnited States National Institutes of Healthadaptive immune responseanti-CTLA4anti-PD-1anti-PD1 antibodiesanti-PD1 therapyantitumor effectbasecancer immunotherapycohortcommensal bacteriadysbiosiseffector T cellexhaustexperimental studyfecal transplantationgut microbiomegut microbiotaimmune checkpoint blockadeinter-individual variationmelanomamicrobiota profilesmouse modelnovelpembrolizumabprogrammed cell death ligand 1programmed cell death protein 1receptorreconstitutionresponsesextumortumor growthtumor immunology
项目摘要
Abstract
There is ample evidence that melanoma patients (MPs) develop immune responses directed against tumor-
associated antigens. However, high frequencies of tumor antigen-specific cytotoxic T-lymphocytes (CTL) often
fail to induce tumor rejection. Among the numerous mechanisms of tumor-induced immunosuppression that
contribute to the resistance of tumors to CTL responses, it is now well established that inhibitory receptors like
PD1 play a critical role in dampening T cell responses to tumors. As a result, therapy with blocking anti-PD1
monoclonal antibodies has become one of the most potent therapies of melanoma, providing prolonged clinical
benefits to 30-40% advanced MPs. There is strong evidence that pre-existing CD8+ tumor-infiltrating T cells
correlate with clinical antitumor response to PD1 blockade. However, not all T cell-inflamed tumors respond to
PD1 blockade and not all melanomas are inflamed. Hence, the mechanisms supporting response or resistance
to PD1 blockade remain to be precisely determined. Two studies have shown the role of the gut microbiome in
regulating clinical responses to CTLA4 and PD1 blockade in murine melanoma model. In addition, two studies
in NSCLCs and renal cancers (RC), and melanoma patients (MPs), respectively, have shown that the
presence of certain commensals correlated with better clinical outcome upon PD1 blockade. Fecal microbiota
transplant (FMT) from PD1 responders (PD1Rs) in melanoma-bearing GF mice reduced significantly tumor
growth as compared to FMT from PD1 non-responders (PD1NRs). We have observed the increased
abundance of certain bacterial commensals in stools of PD1Rs as compared to PD1NRs, albeit significantly
different from the ones recently published. The striking differences between our findings and the recent
published study are not totally surprising when one considers the greater complexity and inter-individual
variability of the human gut microbiota upon many host-dependent variables. It is therefore critically important
to expand these studies in a larger number of MPs using state-of-the-art omic approach (metagenomics) and
Systems Biology to evaluate the direct causality between commensal bacteria and clinical outcome. Here, we
propose to test whether the gut microbiome modulates immune and clinical responses to PD1 blockade in the
context a novel clinical trial with FMT obtained from PD1Rs combined with PD1 blockade in PD1NRs. This
project will test the novel hypotheses that: 1) PD1Rs exhibit distinct gut microbiota profiles in terms of diversity,
abundance and dynamics over time compared with PD1NRs; 2) the administration of single PD1R-derived
FMT to a PD1NRs together with PD1 blockade promotes clinical antitumor response; and 3) the occurrence of
clinical responses in MPs treated with FMT and PD1 blockade correlates with T cell responses to melanoma.
This proposal will take advantage of the well-established and cross-disciplinary expertise of the investigators in
melanoma, human cancer immunology, gut microbiome and metaomics, biostatistics, and systems biology.
摘要
有充分的证据表明,黑色素瘤患者(MP)会产生针对肿瘤的免疫反应,
相关抗原。然而,高频率的肿瘤抗原特异性细胞毒性T淋巴细胞(CTL)通常
不能诱导肿瘤排斥反应。在肿瘤诱导的免疫抑制的众多机制中,
有助于肿瘤对CTL应答的抗性,现在已经确定抑制性受体如
PD 1在抑制T细胞对肿瘤的反应中起关键作用。因此,使用阻断性抗PD 1抗体的治疗
单克隆抗体已经成为黑色素瘤最有效的治疗方法之一,
30-40%的高级议员受益。有强有力的证据表明,预先存在的CD 8+肿瘤浸润性T细胞
与对PD 1阻断的临床抗肿瘤反应相关。然而,并不是所有的T细胞炎症肿瘤都对
PD 1阻断,并不是所有的黑色素瘤都会发炎。因此,支持反应或抵抗的机制
对PD 1的阻断作用仍有待精确测定。两项研究表明,肠道微生物组在
在鼠黑素瘤模型中调节对CTLA 4和PD 1阻断的临床应答。此外,还有两项研究
在NSCLC和肾癌(RC)和黑色素瘤患者(MP)中,分别显示,
某些药物的存在与PD 1阻断后更好的临床结果相关。粪便微生物群
在携带黑色素瘤的GF小鼠中,来自PD 1应答者(PD 1 R)的移植物(FMT)显著减少了肿瘤
与来自PD 1无应答者(PD 1 NRs)的FMT相比的生长。我们观察到,
与PD 1 NR相比,PD 1 R粪便中某些细菌的丰度,尽管显著
与最近出版的不同。我们的研究结果与最近的研究结果之间的显著差异
当人们考虑到更大的复杂性和个体间的差异时,
人类肠道微生物群的变异性取决于许多宿主依赖性变量。因此,
使用最先进的组学方法(宏基因组学)在大量MP中扩展这些研究,
系统生物学评价肠道细菌与临床结局之间的直接因果关系。这里我们
建议测试肠道微生物组是否调节免疫和临床对PD 1阻断的反应,
背景是一项新的临床试验,FMT从PD 1 Rs中获得,与PD 1 NR中的PD 1阻断相结合。这
该项目将测试以下新假设:1)PD 1 R在多样性方面表现出不同的肠道微生物群特征,
与PD 1 NRs相比,随着时间的推移的丰度和动力学; 2)施用单一PD 1 R衍生的
针对PD 1 NR的FMT与PD 1阻断一起促进临床抗肿瘤应答;和3)
用FMT和PD 1阻断剂治疗的MP的临床应答与T细胞对黑素瘤的应答相关。
这一提议将利用调查员在以下方面的成熟和跨学科的专门知识:
黑色素瘤,人类癌症免疫学,肠道微生物组和元组学,生物统计学和系统生物学。
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy.
癌症免疫疗法中肠道菌群干预措施的事实和希望。
- DOI:10.1158/1078-0432.ccr-21-1129
- 发表时间:2022-10-14
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
- DOI:10.1158/1078-0432.ccr-20-0575
- 发表时间:2020-10-15
- 期刊:
- 影响因子:0
- 作者:Chauvin JM;Ka M;Pagliano O;Menna C;Ding Q;DeBlasio R;Sanders C;Hou J;Li XY;Ferrone S;Davar D;Kirkwood JM;Johnston RJ;Korman AJ;Smyth MJ;Zarour HM
- 通讯作者:Zarour HM
Targeting novel inhibitory receptors in cancer immunotherapy.
- DOI:10.1016/j.smim.2020.101436
- 发表时间:2020-06
- 期刊:
- 影响因子:7.8
- 作者:Ding QQ;Chauvin JM;Zarour HM
- 通讯作者:Zarour HM
Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients.
- DOI:10.1097/cmr.0000000000000871
- 发表时间:2023-04-01
- 期刊:
- 影响因子:2.2
- 作者:Fortman, Dylan;Avellan, Maria G. Pazan;Hurd, Drew;Schwartz, Marc;Dubner, Howard;Hewitt, Corey;Berton, Samantha;Ernst, Scarlett;Rose, Amy;Wang, Hong;Zarour, Hassane;Davar, Diwakar
- 通讯作者:Davar, Diwakar
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HASSANE M ZAROUR其他文献
HASSANE M ZAROUR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HASSANE M ZAROUR', 18)}}的其他基金
Project 2: Immunotherapy with CMP-001 intratumoral and nivolumab in melanoma
项目 2:使用 CMP-001 瘤内注射和纳武单抗治疗黑色素瘤的免疫疗法
- 批准号:
10683757 - 财政年份:2021
- 资助金额:
$ 50.51万 - 项目类别:
Project 2: Immunotherapy with CMP-001 intratumoral and nivolumab in melanoma
项目 2:使用 CMP-001 瘤内注射和纳武单抗治疗黑色素瘤的免疫疗法
- 批准号:
10469636 - 财政年份:2021
- 资助金额:
$ 50.51万 - 项目类别:
Project 2: Immunotherapy with CMP-001 intratumoral and nivolumab in melanoma
项目 2:使用 CMP-001 瘤内注射和纳武单抗治疗黑色素瘤的免疫疗法
- 批准号:
10270232 - 财政年份:2021
- 资助金额:
$ 50.51万 - 项目类别:
Fecal Microbiota Transplant and PD-1 blockade in Melanoma
黑色素瘤中的粪便微生物群移植和 PD-1 阻断
- 批准号:
10018469 - 财政年份:2018
- 资助金额:
$ 50.51万 - 项目类别:
Fecal Microbiota Transplant and PD-1 blockade in Melanoma
黑色素瘤中的粪便微生物群移植和 PD-1 阻断
- 批准号:
10196995 - 财政年份:2018
- 资助金额:
$ 50.51万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 50.51万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 50.51万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 50.51万 - 项目类别:
Fellowship
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 50.51万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 50.51万 - 项目类别:
Continuing Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 50.51万 - 项目类别:
Standard Grant
The economics of (mis)information in the age of social media
社交媒体时代(错误)信息的经济学
- 批准号:
DP240103257 - 财政年份:2024
- 资助金额:
$ 50.51万 - 项目类别:
Discovery Projects
How age & sex impact the transcriptional control of mammalian muscle growth
你多大
- 批准号:
DP240100408 - 财政年份:2024
- 资助金额:
$ 50.51万 - 项目类别:
Discovery Projects
Supporting teachers and teaching in the age of Artificial Intelligence
支持人工智能时代的教师和教学
- 批准号:
DP240100111 - 财政年份:2024
- 资助金额:
$ 50.51万 - 项目类别:
Discovery Projects
Enhancing Wahkohtowin (Kinship beyond the immediate family) Community-based models of care to reach and support Indigenous and racialized women of reproductive age and pregnant women in Canada for the prevention of congenital syphilis
加强 Wahkohtowin(直系亲属以外的亲属关系)以社区为基础的护理模式,以接触和支持加拿大的土著和种族育龄妇女以及孕妇,预防先天梅毒
- 批准号:
502786 - 财政年份:2024
- 资助金额:
$ 50.51万 - 项目类别:
Directed Grant